Enrollment Milestone Achieved in MyPEAK™-1 and RIDGE™-1 Clinical Trials
August 6, 2025 - 23:19
Tenaya Therapeutics has announced significant progress in its clinical trials, marking a pivotal moment for its innovative therapies targeting specific heart conditions. The enrollment process for Cohorts 1 and 2 of the MyPEAK™-1 Phase 1b/2 trial of TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM), has been successfully completed. This achievement has been bolstered by a positive safety review from the Data Safety Monitoring Board (DSMB), which has now allowed the company to proceed with the enrollment of expansion cohorts.
In addition, the RIDGE™-1 Phase 1b trial of TN-401 has also made strides, with Cohort 1 fully enrolled and the first patient with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) dosed in Cohort 2. This advancement follows the DSMB's recommendation to escalate dosing and expand the trial.
Tenaya Therapeutics is set to provide data readouts from both clinical programs in the fourth quarter of 2025, with a cash runway projected to extend into the second half of 2026, ensuring continued development of these promising therapies.
MORE NEWS
July 7, 2026 - 00:52
New Mountain Finance Corporation Schedules its Second Quarter 2026 Earnings Release and Conference CallNEW YORK, July 6, 2026 - New Mountain Finance Corporation (NASDAQ: NMFC) announced today that it plans to publish its financial results for the second quarter of 2026 on Monday, August 3, after the...
July 6, 2026 - 01:10
Here is Why Yext (YEXT) is One of the Best Value Penny Stocks to Buy According to Hedge FundsYext Inc. (NYSE:YEXT) is gaining attention from hedge funds as one of the best value penny stocks to buy right now. The company recently reported its financial results for the first quarter of...
July 5, 2026 - 17:54
'It's a bull market': Wall Street sees more upside in stocks for the second half of 2026The stock market ended the first quarter on a high note, and major Wall Street firms are now forecasting continued momentum through the second half of the year. Analysts point to resilient...
July 4, 2026 - 21:25
Meet the High-Yield Dividend Stock That's Quietly Crushing the S&P 500 and Nasdaq. Here's Why There's Plenty of Room to Run.Most investors have never heard of this company, but its stock is up 30% year to date. That performance has quietly crushed both the S&P 500 and the Nasdaq composite, which have struggled to stay...